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Poster Session I S259specific TCRs in recipient effector cells is an attractive new treat-
ment modality for patients after allogeneic stem cell transplantation
who are at high risk of infection. Themajority of CD8+T cells express
the conventional CD8ab heterodimer at the cell surface, while a subset
of CD8+ T cells express the CD8aa homodimer. CD8aa and CD8ab
interact both with MHC-I molecule. CD8aa acts as a co-receptor, al-
though with less efficiency as compared to CD8ab. Preferential ex-
pression of CD8aa may represent a mechanism modulating the
avidity of CD8+ T cells. CD8aa+ T cells display an effector memory
and terminally differentiated phenotype and are believed to derive
from CD8ab+ T cells that have down-regulated CD8b chain expres-
sion. We have identified CD8aa+ T cells in the peripheral blood cir-
culation in human healthy donors and in non-human primates (5%
and 16% respectively of CD8+ T cells) and defined their differentia-
tion status based on CD45RA, CCR7, CD27, and CD28 expression.
We showed for the first time that patients with melanoma, who re-
sponded successfully to peptide-based vaccination, showed Melan-A/
MART-1-specific T cells in the CD8aa+ T cell compartment. In
one patient (with stage IV melanoma and experienced full remission
after immunological therapy) Melan-A/MART-1-specific CD8aa+
T cells were detected up to five years after vaccination. This provides
support that CD8aa+ T cells may be instrumental in mediating clin-
ically relevant, long-lived, anti-tumor immune responses. The impact
of CD8aa and CD8ab expression in modulating T cell avidity as well
as the specific T cell signaling associated with transgenic TCRs is be-
ing evaluated in an in vitro model (insect cells and Jurkat T cells) by
assessing effector functions (e.g. proliferation, cytokine production),
and signaling cascades. We hypothesize that CD8aa+ T cells repre-
sent a novel compartment of long-lived memory T cells endowed
with CD8-independent high affinity TCRs. Such high avidity
TCRs, recognizing viral targets (i.e. CMV, EBV), are present in the
CD8aa+ T cell compartment and represent viable targets for passive
immune-therapy of infections after transplantation.149
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Despite autologous stem cell transplant (ASCT), relapse is inevi-
table for patients withmultiplemyeloma (MM).MM is thought to be
derived from MM cancer stem cells (MMCSC) that express CD20
providing a unique target for activated T cells (ATC) armed with
anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) that binds to
T cells and to CD20 on MMSCS. CD20Bi armed ATC can kill rit-
uximab-resistant CD20+ lymphoma cells (Exp Hemat 33:452). We
tested whether targeting CD20 onMMCSC prior to ASCTwould in-
duce anti-MMCSC immunity that could be transferred in the stem cell
product during ASCT. A phase Ib clinical trial was performed to de-
termine safety, and the development of anti-myeloma immunity before
and after ASCT in 12 patients (pts). Pts were given 2 infusions of 1010
aATC 1 week apart (immunotherapy 5 IT) after myeloma induction
therapy prior to ASCT.Twelve patients were consented and evaluable
for safety, blood and bone marrow phenotyping, cytotoxicity, and
IFNg Elispot before IT, after IT, and after ASCT. Twelve patients
are surviving between 190 and 615 days after ASCT. There were no
dose-limiting toxicities or delays in engraftment. IFNg EliSpots in-
creased in 5 out 12 pts directed at Daudi, 6 out of 12 at K562, and 5
out of 12 at RPMI 8226 after IT in patients compared to before IT.
Increased IFNgEliSpotswere also detected inPBMC from5of 12 pa-
tients directed atRPMI 8226 after ASCT. PBMC from5of 12patients
had detectable anti-RPMI 8226 responses after ASCTwithout a boost
and 3 of 3 patients that were boosted with a single infusion of CD20Bi
armed ATC at 6.5, 10.5, and 15.2 months after ASCT showed in-
creased anti-RPMI 8226 IFNg EliSpot responses from 200 to 610,
75 to 190, and 100 to 200 EliSpots per 106 PBL plated. These data
strongly suggest that targeting MMSCS with CD20Bi armed ATCcan induce immunity that can be detected after ASCT and this immu-
nity can be boosted by an additional single infusion of armed ATC be-
yond 6months after ASCT. Immune studies suggest that targeting can
immunize the patient’s immune system against antigens on MMCSC
and the process of ASCT can transfer this immunity and the immunity
can be boosted.150
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Background: Relapse remains the primary cause of failure of al-
loHSCT for hematologic malignancies, and treatment, including
DLI, is often incompletely effective. Cancer vaccines have the poten-
tial to enhance the graft-vs-leukemia effect associated with DLI.
This pilot trial utilizes a novel allogeneic donor-derived DC vaccine
that targets WT1, a tumor-associated antigen commonly expressed
in hematologic malignancies. The objectives are to assess safety, tox-
icity, feasibility, immune responses, and clinical activity of WT1-
peptide loaded DCs and DLI for children and adults with relapsed
hematologic malignancies after alloHSCT.
Design: Patients with hematologic malignancies that are WT1+
(immunohistochemistry or quantitative RT-PCR) and have relapsed
after alloHSCT are eligible. Donors (related, unrelated) and patients
must be HLA-A2+. Donor peripheral blood monocyte-derived DCs
are loaded with a combination of 3 HLA-A2 bindingWT1 peptides
linked to the 11-merHIVTAT peptide designed to enhance antigen
presentation. Treatment consists of vaccines (10 x 106 DCs subcuta-
neous and 2 x 106 DCs intradermal) every 2 weeks for 6 doses and
DLI (1 x 106 CD3+ T-cells/kg) every 4 weeks for 3 doses.
Results: 4 patients, 11-18 years of age have been treated; 3 with
acute lymphoblastic leukemia (ALL) and one with Hodgkin lym-
phoma. Donors were matched siblings in 3 cases and a 10/10 HLA
matched father in one case. Vaccines were successfully produced
from all donors. Vaccine and DLI administrations were well toler-
ated. The most common adverse events were mild, reversible pain
and pruritus at sites of vaccine and delayed type hypersensitivity
(DTH) skin test administration. One patient developed Grade I
skin GVHD that did not require treatment. 3 of 4 (75%) patients
had positive ELISPOT responses toWT1 peptides. DTH responses
to WT1 were seen in 2 of 4 (50%) and to the keyhole limpet hemo-
cyanin (KLH) control in 3 of 4 (75%). Immune responses were ob-
served in all 3 patients with ALL. Median overall survival was 12
months. 1 patient with ALL achieved complete remission without
evidence for disease by flow cytometry. 3 patients have died of dis-
ease.
Conclusions:This novel allogeneic immunotherapy regimen is fea-
sible, well tolerated, and associated with immune responses. This ap-
proach has the potential to augment the efficacy of DLI in the
management of post-transplant relapse of hematologic malignan-
cies. Accrual is ongoing.
Table. Patient Characteristics and Immune Responses










DTHALL 18/F NMA/MSD 8 14 + + +Hodgkin’s 18/M NMA/MSD 1 32 - - -ALL 15/M MA/MSD 12 14 + - +ALL 11/M MA/MRD 11 29 + + +
